PubMed:32736597 / 4631-4927 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T12 148-151 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T13 260-263 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T5 148-151 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T6 260-263 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T53 148-151 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T54 260-263 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T33 0-296 Sentence denotes The primary endpoint/outcome measure for this trial is: for Group 1, the proportion of subjects who become symptomatic and/or swab-positive in each arm within one month of randomization; for Group 2, the proportion of subjects who become swab-negative in each arm within 14 days of randomization.